PBT2 from the Doherty Institute news site., page-14

[Prana Secures Key PBT2 Patents in the United States and Europe
Patents Support Pipeline Opportunities for PBT2 in AD and HDAugust 24, 2010: 08:48 AM ETPrana Biotechnology (NASDAQ: PRAN) (ASX: PBT) today announced that it has secured key PBT2 patents in Europe and the United States.The United States Patent and Trademark Office (USPTO) has Granted a composition of matter patent for selected 8-hydroxyquinoline compounds, including its lead clinical asset, PBT2, in the United States. The patent titled '8-Hydroxyquinoline derivatives' also covers pharmaceutical compositions containing PBT2 and selected 8-hydroxyquinoline compounds.The USPTO has additionally extended the term of this patent by approximately 2.5 years resulting in an expiry date calculated to be 21 December 2025. This expiry date may in the future be further extended by the application of pharmaceutical extension of term provisions in that country.Since previously announcing the grant of the related European case, the company is also pleased to confirm the expiry of the mandatory 9 month post-grant opposition period whereby third parties can register objections. Absent any third party opposition, the European case has now been placed on the Register of European patents.The European patent has a twenty year term expiring on 16 July 2023, with a possible extension of term of up to 5 years under supplementary protection provisions.]
Maybe PBT2 can be relatively fast to market.